Chemotherapy News and Research

Latest Chemotherapy News and Research

Breast cancer risks and management updates

A new report that looks at the environmental factors that affect risk of breast cancer is out. It suggests that women can reduce their risk by avoiding unnecessary medical radiation, forgoing hormone treatments for menopause that combine estrogen and progestin, limiting alcohol intake and minimizing weight gain.

8 Dec 2011

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.

8 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated results of a Phase III study of Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing.

8 Dec 2011

Majority of women do not receive guideline-recommended breast cancer adjuvant therapy

A first-of-its kind study led by Xiao-Cheng Wu, MD, MPH, Associate Professor of Public Health at LSU Health Sciences Center New Orleans, reports that a significant number of women are not receiving guideline-recommended treatment for breast cancer and what factors contribute.

7 Dec 2011

TAU develops tumor destruction method that also creates immunity

Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal.

7 Dec 2011

FDA modifies requirements of Amgen's Nplate REMS Program

Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.

7 Dec 2011

Breast cancer patients might experience prolonged fatigue years after chemotherapy

In a follow-up study, researchers at Moffitt Cancer Center and colleagues have found that patients who receive chemotherapy for breast cancer might experience prolonged fatigue years after their therapy.

6 Dec 2011

Acupuncture for chemotherapy-induced peripheral neuropathy

Acupuncture may help ease the severe nerve pain associated with certain cancer drugs, suggests a small preliminary study published in Acupuncture in Medicine.

5 Dec 2011

Genetic variation predicts survival chances of ovarian cancer

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

5 Dec 2011

P-Rex1 gene plays a key role in the spread of malignant melanoma

SCIENTISTS in Glasgow have made an important discovery in the fight against malignant melanoma, the most dangerous form of skin cancer.

5 Dec 2011

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

When the American Society of Hematology convenes its 53rd Annual Meeting and Exposition on Dec. 10-13 in San Diego, Calif., researchers from Moffitt Cancer Center will break a new record for Moffitt participants with one plenary presentation, 16 oral presentations and more than 50 poster presentations on new research results in a variety of meeting programs that focus on blood cancer basic science and clinical applications, including bone marrow transplantation and clinical trials results.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Four clinical centers to provide NovoTTF device treatment for recurrent GBM

Novocure, a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields) device, NovoTTF-100A System, for the treatment of recurrent glioblastoma multiforme. GBM is a deadly brain tumor affecting approximately 10,000 Americans each year.

3 Dec 2011

Promising new agent against sarcomas affecting children

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.

3 Dec 2011

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.

3 Dec 2011

University of Illinois Hospital prescribes Tumor Treating Fields therapy for recurrent GBM

The University of Illinois Hospital is the first center in North America to prescribe a new FDA-approved treatment for patients with the most common and aggressive type of brain tumor, glioblastoma multiforme, or GBM.

3 Dec 2011

MK 1775 shows promise against sarcomas

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla.

3 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Breast cancer risks and management updates

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Majority of women do not receive guideline-recommended breast cancer adjuvant therapy

TAU develops tumor destruction method that also creates immunity

FDA modifies requirements of Amgen's Nplate REMS Program

Breast cancer patients might experience prolonged fatigue years after chemotherapy

Acupuncture for chemotherapy-induced peripheral neuropathy

Genetic variation predicts survival chances of ovarian cancer

P-Rex1 gene plays a key role in the spread of malignant melanoma

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Four clinical centers to provide NovoTTF device treatment for recurrent GBM

Promising new agent against sarcomas affecting children

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

University of Illinois Hospital prescribes Tumor Treating Fields therapy for recurrent GBM

MK 1775 shows promise against sarcomas

Treatments for lymphoma with no side effects

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in